Literature DB >> 1726836

Insulin-like growth factor binding proteins (IGFBPs) in acromegaly.

V J Coulson1, J A Wass, A F Abdulla, A M Cotterill, J M Holly.   

Abstract

Hypersecretion of growth hormone (GH) is the principal feature of acromegaly and is accompanied by an excess of IGF-I production which mediates some of the actions of GH. The activity of IGF-I is modulated by a number of specific binding proteins (IGFBPs) which form complexes with IGF-I in the circulation. In this study, the technique of Western Ligand Blotting followed by 2-dimensional radioactive scanning was employed to investigate the correlations between relative levels of the IGFBPs and the main factors implicated in their regulation: IGF-I, GH and insulin, in a group of acromegalics with varying disease activity. The two glycosylated forms of IGFBP-3 correlated with increased levels of IGF-I (40.5 kD, r = 0.468, p < or = 0.01 and 36.5 kD, r = 0.809, p < or = 0.001), but did not relate to mean GH levels. Quantification of IGFBP-2 on the ligand blot showed an association with RIA levels of IGFBP-1 (r = 0.35, p < or = 0.05). IGFBP-1 RIA levels did not relate to the radioactivity in the assumed IGFBP-1 region of the ligand blot. This may be explained by fragments of IGFBP-3 running in this region and could account for the correlation seen between radioactivity in the 29 kD band with both forms of IGFBP-3 as well as with IGFBP-4. IGFBP-3 levels were normal in biochemically cured acromegalics with normal GH levels, although fasting insulin levels remained higher than normal (mean 16 +/- 4 vs normal 7.4 +/- 0.4 mU/L).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1726836

Source DB:  PubMed          Journal:  Growth Regul        ISSN: 0956-523X


  2 in total

1.  Alterations in the insulin-like growth factor system during treatment with diethylstilboestrol in patients with metastatic breast cancer.

Authors:  S I Helle; J Geisler; G B Anker; B Leirvaag; J M Holly; P E Lønning
Journal:  Br J Cancer       Date:  2001-07-20       Impact factor: 7.640

2.  Microencapsulated octreotide pamoate in advanced gastrointestinal and pancreatic cancer: a phase I study.

Authors:  S I Helle; J Geisler; J P Poulsen; K Hestdal; K Meadows; W Collins; K M Tveit; J M Holly; P E Lønning
Journal:  Br J Cancer       Date:  1998-07       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.